Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Kidney Diseases Clear all
Completed Phase 2 Interventional Results available

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

NCT03173560
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
lenvatinib, everolimus
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
8
States / cities
Duarte, California • Whittier, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Sep 17, 2026, 4:18 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Metastatic Renal Cell Carcinoma

NCT04831138
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
MRI with ASL, ASL-MRI
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 17, 2026, 4:18 AM EDT
Suspended Phase 4 Interventional Accepts healthy volunteers

Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury

NCT05435235
View directory record Official record
Conditions
Acute Kidney Injury, Percutaneous Coronary Intervention
Interventions
Dapagliflozin 10mg Tab
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Sep 17, 2026, 4:18 AM EDT
Not listed Phase 4 Interventional

A Crossover Pilot Study of the Effect of Amiloride on Proteinuria

NCT02522650
View directory record Official record
Conditions
Proteinuria
Interventions
Amiloride, Triamterene
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Sep 17, 2026, 4:18 AM EDT
Recruiting Phase 1 Interventional

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

NCT06805825
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma, Neuroendocrine Tumors, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Interventions
NN3201
Drug
Lead sponsor
Novelty Nobility, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Ann Arbor, Michigan • Cleveland, Ohio • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 17, 2026, 4:18 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

NCT06270706
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumor
Interventions
PLN-101095, Pembrolizumab
Drug
Lead sponsor
Pliant Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
12
States / cities
New Haven, Connecticut • Atlanta, Georgia • Grand Rapids, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 17, 2026, 4:18 AM EDT
Completed Phase 4 Interventional Results available

Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.

NCT03183778
View directory record Official record
Conditions
Chronic Kidney Diseases, Hyperkalemia
Interventions
Patiromer, Research Diet Menu
Drug · Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Sep 17, 2026, 4:18 AM EDT
Terminated Phase 3 Interventional Results available

A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

NCT00422513
View directory record Official record
Conditions
Anemia
Interventions
methoxy polyethylene glycol-epoetin beta, Epoetin alfa
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
44
States / cities
Birmingham, Alabama • Rainbow City, Alabama • Hot Springs, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2011 · Synced Sep 17, 2026, 4:18 AM EDT
Completed Phase 2 Interventional Results available

DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC

NCT00085436
View directory record Official record
Conditions
Kidney Cancer
Interventions
Aldesleukin,, autologous tumor cell vaccine, recombinant interferon alfa
Biological
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Sep 17, 2026, 4:18 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria

NCT03449199
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
TMX-049, Placebo
Drug
Lead sponsor
Teijin America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
55
States / cities
Flagstaff, Arizona • Mesa, Arizona • Alhambra, California + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Sep 17, 2026, 4:18 AM EDT
Completed Phase 3 Interventional Results available

Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1

NCT02770716
View directory record Official record
Conditions
Hepatorenal Syndrome
Interventions
Terlipressin, Placebo
Drug · Other
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
59
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Sep 17, 2026, 4:18 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Near Infrared Spectroscopy for the Detection of Acute Kidney Injury in Children Following Cardiac Surgery

NCT01382758
View directory record Official record
Conditions
Acute Kidney Injury, Heart; Dysfunction Postoperative, Cardiac Surgery, Children
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
1 Day to 4 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 17, 2026, 4:18 AM EDT
Completed Phase 4 Interventional Results available

Novartis Everolimus Transition

NCT02096107
View directory record Official record
Conditions
Graft Dysfunction, Interstitial Fibrosis
Interventions
Everolimus, Standard of Care
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Sep 17, 2026, 4:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3473329 in Participants With Impaired and Normal Renal Function

NCT05778864
View directory record Official record
Conditions
Renal Insufficiency
Interventions
LY3473329
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Edgewater, Florida • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2024 · Synced Sep 17, 2026, 4:18 AM EDT
Recruiting Phase 2 Interventional

Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

NCT07023432
View directory record Official record
Conditions
Active Surveillance, Clear Cell Renal Cell Carcinoma
Interventions
Belzutifan, Active Surveillance
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 17, 2026, 4:18 AM EDT
Completed Phase 2 Interventional Results available

Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection

NCT00801632
View directory record Official record
Conditions
Kidney Transplantation, Kidney Failure, Chronic
Interventions
Kidney Transplantation, Bone marrow transplantation, MEDI-507, cyclophosphamide, rituximab, Tacrolimus, corticosteroids, thymic irradiation
Procedure · Biological · Drug + 1 more
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 9, 2015 · Synced Sep 17, 2026, 4:18 AM EDT
Completed Phase 1 Interventional

Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors

NCT00011414
View directory record Official record
Conditions
Wilms' Tumor, Sarcoma, Adenaocortical Carcinoma, Refractory Cancer, Coldrhood Cancer
Interventions
Tariquidar
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 18 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 17, 2026, 4:18 AM EDT
Terminated Phase 2Phase 3 Interventional

COOL RCN: Cooling to Prevent Radiocontrast Nephropathy

NCT00306306
View directory record Official record
Conditions
Renal Failure, Kidney Failure, Renal Insufficiency
Interventions
Reprieve Endovascular Temperature Therapy System
Device
Lead sponsor
Radiant Medical
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Sep 17, 2026, 4:18 AM EDT
Completed Early Phase 1 Interventional

Pilot Randomized-controlled Trial of Integrated Palliative and Nephrology Care Versus Usual Nephrology Care.

NCT04520984
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Integrated ambulatory palliative and nephrology care, Standard nephrology care
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Sep 17, 2026, 4:18 AM EDT
Enrolling by invitation Not applicable Interventional

Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease

NCT05514184
View directory record Official record
Conditions
Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), CKD Stage 3, CKD Stage 4, CKD Stage 5, Diabetes Mellitus, Diabetic Kidney Disease
Interventions
PLAFOND diet
Dietary Supplement
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Orange, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 17, 2026, 4:18 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis

NCT02138838
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions
Cinacalcet HCl, Standard of Care
Drug · Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
26
States / cities
Los Angeles, California • Wilmington, Delaware • Atlanta, Georgia + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2020 · Synced Sep 17, 2026, 4:18 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Patients With Heart Disease Not Eligible for Research Protocols

NCT00001458
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Up to 99 Years
Enrollment
7,829 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Sep 17, 2026, 4:18 AM EDT
Completed Phase 4 Interventional

Pilot Study for HLA Identical Living Donor Renal Transplant Recipients

NCT00352092
View directory record Official record
Conditions
Renal Transplant
Interventions
calcineurin inhibitor, sirolimus, mycophenolate mofetil
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 12, 2014 · Synced Sep 17, 2026, 4:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of RBT-3 in Healthy Volunteers and Volunteers With Stage 3/4 Chronic Kidney Disease

NCT04072432
View directory record Official record
Conditions
Healthy Volunteers, Chronic Kidney Disease
Interventions
RBT-3
Drug
Lead sponsor
Renibus Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Edgewater, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Sep 17, 2026, 4:18 AM EDT